Market closed
IDEAYA Biosciences/$IDYA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About IDEAYA Biosciences
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.
Ticker
$IDYA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
124
Website
IDYA Metrics
BasicAdvanced
$2.7B
Market cap
-
P/E ratio
-$2.34
EPS
0.86
Beta
-
Dividend rate
Price and volume
Market cap
$2.7B
Beta
0.86
52-week high
$47.74
52-week low
$27.52
Average daily volume
733K
Financial strength
Current ratio
22.928
Quick ratio
22.628
Long term debt to equity
1.592
Total debt to equity
1.592
Management effectiveness
Return on assets (TTM)
-15.85%
Return on equity (TTM)
-21.10%
Valuation
Price to revenue (TTM)
601.635
Price to book
2.27
Price to tangible book (TTM)
2.27
Price to free cash flow (TTM)
-15.395
Growth
Revenue change (TTM)
-83.30%
Earnings per share change (TTM)
20.45%
3-year revenue growth (CAGR)
-52.04%
3-year earnings per share growth (CAGR)
28.02%
What the Analysts think about IDYA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for IDEAYA Biosciences stock.
IDYA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
IDYA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
IDYA News
AllArticlesVideos
Biocytogen Announces IDEAYA's Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
Business Wire·3 days ago
Biocytogen Announces IDEAYA's Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
Business Wire·3 days ago
Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for IDEAYA Biosciences stock?
IDEAYA Biosciences (IDYA) has a market cap of $2.7B as of November 14, 2024.
What is the P/E ratio for IDEAYA Biosciences stock?
The price to earnings (P/E) ratio for IDEAYA Biosciences (IDYA) stock is 0 as of November 14, 2024.
Does IDEAYA Biosciences stock pay dividends?
No, IDEAYA Biosciences (IDYA) stock does not pay dividends to its shareholders as of November 14, 2024.
When is the next IDEAYA Biosciences dividend payment date?
IDEAYA Biosciences (IDYA) stock does not pay dividends to its shareholders.
What is the beta indicator for IDEAYA Biosciences?
IDEAYA Biosciences (IDYA) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.